125 related articles for article (PubMed ID: 26481183)
1. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Taga T; Watanabe T; Tomizawa D; Kudo K; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Shimada A; Taki T; Toki T; Ito E; Goto H; Koh K; Saito AM; Horibe K; Nakahata T; Tawa A; Adachi S
Pediatr Blood Cancer; 2016 Feb; 63(2):248-54. PubMed ID: 26481183
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
[TBL] [Abstract][Full Text] [Related]
3. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
4. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
5. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Tan RM; Quah TC; Aung L; Liang S; Kirk RC; Yeoh AE
Pediatr Blood Cancer; 2007 Mar; 48(3):262-7. PubMed ID: 16602120
[TBL] [Abstract][Full Text] [Related]
7. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
10. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
11. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
13. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
14. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
15. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
[TBL] [Abstract][Full Text] [Related]
17. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
18. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
[TBL] [Abstract][Full Text] [Related]
19. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
